USA
Analytical Standards
Controlled Research Environment
Research Product
IGF-1 LR3
1. Product Overview
IGF-1 LR3 (Long R3 Insulin-Like Growth Factor-1) is a modified analogue of Insulin-Like Growth Factor-1 engineered for research involving growth factor signaling, cellular proliferation, protein expression, and receptor-mediated biological pathways. It has attracted significant scientific interest in studies focused on cellular growth mechanisms, tissue development, metabolic regulation, and peptide-based signaling processes. IGF-1 LR3 is supplied as a lyophilized research peptide and undergoes analytical testing to verify identity, purity, and consistency.
Manufactured in a controlled research environment, this product is intended exclusively for laboratory and scientific research applications.
2. Specifications
| Product Name | IGF-1 LR3 | Testing Method | HPLC |
|---|---|---|---|
| Synonym | Long R3 Insulin-Like Growth Factor-1 | Storage Condition | 2-8C |
| Format | Lyophilized Powder | Shelf Life | 24 Months |
| Content | 0.25mg per vial | Manufacturing Standard | GMP Standard Research Environment |
| Purity | >=99% HPLC | Country of Origin | USA |
| Appearance | White to Off White Lyophilized Powder | Intended Use | Research Use Only |
3. Research Summary
IGF-1 LR3 (Long R3 Insulin-Like Growth Factor-1) is a modified analogue of Insulin-Like Growth Factor-1 engineered to exhibit altered receptor interaction characteristics for research purposes. It has attracted significant scientific interest in studies involving growth factor signaling, cellular proliferation, protein synthesis pathways, tissue development, metabolic regulation, and receptor-mediated biological processes.
Research involving IGF-1 LR3 has explored its interaction with IGF-1 receptors, cellular communication networks, growth factor-mediated signaling pathways, and tissue adaptation mechanisms. Ongoing laboratory investigations continue to evaluate its role within cellular growth, differentiation, and regenerative biology research models.
4. Scientific References
- Francis GL, Aplin SE, Milner SJ, McNeil KA, Ballard FJ, Wallace JC. Insulin-like growth factor-I analogues and receptor interactions. Biochemical Journal. 1993;293(3):713-719.
- Tomas FM, Knowles SE, Owens PC, Read LC, Chandler CS, Gargosky SE, Ballard FJ. Biological activity of insulin-like growth factor analogues in growth factor research. Biochemical Journal. 1992;282(1):91-97.
- Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: Biological actions. Endocrine Reviews. 1995;16(1):3-34.
- LeRoith D, Bondy C, Yakar S, Liu JL, Butler A. The Somatomedin Hypothesis: Growth hormone and IGF-I biology. Endocrine Reviews. 2001;22(1):53-74.
- Yakar S, Werner H, Rosen CJ. Insulin-like growth factors: Actions and signaling pathways. Endocrine Reviews. 2018;39(4):575-620.
Disclaimer: This product is intended strictly for research use only. It is not intended for human consumption, clinical application, diagnostic procedures, therapeutic use, veterinary use, or household use. The information provided is for scientific and educational reference purposes only and should not be interpreted as medical advice, treatment guidance, or usage instructions. This product should be handled only by qualified professionals trained in laboratory practices. Purchasers and end users are solely responsible for ensuring compliance with all applicable laws, regulations, and institutional requirements governing the purchase, storage, handling, and use of research materials.
